menorrhagia. Noninflammatory disorders of female genital tract
Conditions
Interventions
Intervention 1: Intervention group:Tranexamic acid capsule 250 mg ,oral, every 8 hour in the first 3 days of bleeding on two subsequent cycles. Intervention 2: Control group:Mefenamic acid capsule 250
Treatment - Drugs
Intervention group:Tranexamic acid capsule 250 mg ,oral, every 8 hour in the first 3 days of bleeding on two subsequent cycles
Control group:Mefenamic acid capsule 250 mg ,oral,every 8 hour in the first 3 days of bleeding on two subsequent cycles
Sponsors
Taleghani Hospital of Tehran
Eligibility
Sex/Gender
Female
Age
15 Years to 49 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: women aged 15-49 suffering from heavy menstrual bleeding or long menstrual duration. Exclusion criteria: organic causes were excluded by history, physical exam, lab test.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Menstrual duration. Timepoint: one month before treatment,two subsequent month during treatment and one month following treatment. Method of measurement: questionnaire.;Menstrual bleeding volume. Timepoint: one month before treatment,two subsequent month during treatment and one month following treatment. Method of measurement: Pictorial chart on which patients marked the type and the number of pads theyused during menstrual bleeding. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complication ,like vertigo, dyspepsia,epigasteric pain,thrombosis. Timepoint: one month following treatment. Method of measurement: questionnaire.;Choosing the drug if the problem recur. Timepoint: one month following treatment. Method of measurement: questionnaire.;Patient satisfaction with the treatment. Timepoint: one month following treatment. Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShiva Hadadian
Taleghani Hospital of Tehran
Outcome results
None listed